title: Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia?
abstract: BACKGROUND
  The efficacy of proton pump inhibitors in functional dyspepsia is modest and the prognostic factors are almost unknown.
  
  
  METHODS
  Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks. Self-administered questionnaires for the assessment of symptoms and health-related quality of life were completed before entry, and epigastric pain/discomfort was recorded on diary cards. Treatment success was defined as the complete absence of epigastric pain/discomfort on each of the last 3 days of week 4. Prognostic factors were identified by multiple logistic regression analysis.
  
  
  RESULTS
  The most discriminating predictor of treatment success (P < 0.0001) was the number of days with epigastric pain/discomfort during the first week of treatment. Fewer days with symptoms during the first week led to higher response rates at 4 weeks. In addition, age > 40 years, bothersome heartburn, low scores for bloating, epigastric pain and diarrhoea, history of symptoms for < 3 months and low impairment of vitality at baseline were identified as positive predictors of outcome.
  
  
  CONCLUSIONS
  Early response to treatment with a proton pump inhibitor, during the first week, seems to predict the outcome after 4 weeks in patients with functional dyspepsia.
authors.affiliation: Department of Biomedicine and Surgery, Linköping, Sweden. elisabeth.bolling-sternevald@astrazeneca.com
authors.forename: E
authors.initials: E
authors.lastname: Bolling-Sternevald
authors.forename: K
authors.initials: K
authors.lastname: Lauritsen
authors.forename: N J
authors.initials: NJ
authors.lastname: Talley
authors.forename: O
authors.initials: O
authors.lastname: Junghard
authors.forename: H
authors.initials: H
authors.lastname: Glise
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D006304:Health Status; D006356:Heartburn / Q000209:etiology; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D054328:Proton Pump Inhibitors; D011788:Quality of Life; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors; D009853:Omeprazole